Screening for prostate cancer

Clinical Prostate Cancer

Volumn 3, Issue 1, 2004, Pages 21-25

  Wilson, Shandra S ^a,b   Crawford, E David ^a  

^a Anschutz Cancer Center   (United States)

^b Anschutz Cancer Center   (United States)

Author keywords

Human kallikrein 2; Prostate specific antigen; Transrectal guided biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER SCREENING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; PREVALENCE; PROSTATE CANCER; REVIEW;

EID: 3442882786     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.008     Document Type: Review

References (49)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Aus G. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment. Scand J Urol Nephrol Suppl 1994; 167:1-41.
3. Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin 1999; 49:264-281.
4. Hakama M, Stenman UH, Aromaa A, et al. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 2001; 166:2189-2191.
5. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
6. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283-1290.
7. Punglia RS, D'Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349:335-342.
8. Liu S, Lee IM, Linson P, et al. A prospective study of physical activity and risk of prostate cancer in US physicians. Int J Epidemiol 2000; 29:29-35.
9. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
10. Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002; 167:103-111.
11. Borboroglu PG, Comer SW, Riffenburgh RH, et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000; 163:158-162.
12. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151:1571-1574.
13. Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glanular zones of the human prostate. J Urol 1995; 153:111-114.
14. Okegawa T, Kinjo M, Ohta M, et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol 2003; 10:201-206.
15. Sokoll LJ, Chan DW, Mikolajczyk SD, et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 2003; 61:274-276.
16. Haese A, Graefen M, Becker C, et al. The role of human landular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003; 54:181-186.
17. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170:442-446.
18. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349:906-910.
19. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347:781-789.
20. Borre M, Nerstrom B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 1997; 80:917-928.
21. Pies LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1973-1999. National Cancer Institute, Bethesda, MD, 2002.
22. Merrill RM, Potosky AL, Feuer EJ. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst 1996; 88:1683-1685.
23. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20:680-688.
24. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368-374.
25. Hirano D, Werahera PN, Crawford ED, et al. Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy. J Urol 1998; 159:1265-1269.
26. Andriole G. Contemporary screening for prostate cancer. Presented at the National Urologic Oncology Update; Newport Beach, CA, 2003.
27. McLaughlin AP, Saltzstein SL, McCullough DL, et al. Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J Urol 1976; 115:89-94.
28. Thompson IM, Ernst JJ, Gangai MP, et al. Adenocarcinoma of the prosrate: results of routine urological screening. J Urol 1984; 132:690-692.
29. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276:1309-1315.
30. Jhaveri FM, Klein EA, Kupelian PA, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999; 17:3167-3172.
31. Gustafsson O, Norming U, Almgard LE, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 1992; 148:1827-1831.
32. Fowler FJ, Jr., Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993; 42:622-629.
33. Catalona WJ, Antenor JA, Roehl KA, et al. Screening for prostate cancer in high risk populations. J Urol 2002; 168:1980-1983.
34. Thompson IM, Optenberg SA. An overview cost-utility analysis of prostate cancer screening. Oncology (Huntingt) 1995; 9(suppl 11):141-145.
35. Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000; 284:1399-1405.
36. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38:83-91.
37. Meyer F, Moore L, Bairati I, et al. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999; 161:1189-1191.
38. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer 2001; 92:893-898.
39. Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999; 161:529-533.
40. Gronberg H, Damber JE, Jonsson H, et al. Patient age as a prognostic factor in prostate cancer. J Urol 1994; 152:892-895.
41. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90:162-173.
42. Crocetti E, Ciatto S, Zappa M. Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy. J Natl Cancer Inst 2001; 93:876-877.
43. Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancerpart III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91:1033-1039.
44. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355:1788-1789.
45. Perron L, Moore L, Bairati I, et al. PSA screening and prostate cancer mortality. CMAJ 2002; 166:586-591.
46. Makinen T, Tammela TL, Hakama M, et al. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen. Clin Cancer Res 2003; 9:2435-2439.
47. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med 1997; 126:394-406.
48. Auvinen A, Rietbergen JB, Denis LJ, et al. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996; 3:97-104.
49. Gohagan JK, Prorok PC, Hayes RB, et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21: 251S-272S.